How CDK4/6 Inhibitors Made a Comeback

Sometimes pre-clinical studies show that a drug has a good chance of helping patients, but when the drug is tested on patients, it doesn't work as expected. Today, we are talking to Dr. Shom Goel, Group Leader and Medical Oncologist at the Peter MacCallum Cancer Centre and the University of Melbourne, in Australia & Komen-funded research scientist. He will talk with us today about the history of CDK4/6 inhibitors - how they initially failed but how scientists continued to work with them and are now seeing some positive results in patients.Special Guest: Dr. Shom Goel.